These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 25377320)

  • 21. Heparin: 100 years of pleiotropic effects.
    Paschoa AF
    J Thromb Thrombolysis; 2016 May; 41(4):636-43. PubMed ID: 26377359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison with other plasma and platelet proteins.
    Williams EC; Huppert BJ; Asakura S
    J Lab Clin Med; 1992 Jul; 120(1):159-67. PubMed ID: 1377216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Edinburgh Orthopaedic Trauma Unit and the International Trauma Symposium.
    Keating JF; White TO
    J Bone Joint Surg Br; 2011 Jul; 93(7):865-6. PubMed ID: 21705554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introduction to the special issue on Clostridium difficile and the history of the International Clostridium difficile Symposium (ICDS).
    Rupnik M; Mastrantonio P
    Anaerobe; 2016 Feb; 37():1-2. PubMed ID: 26856973
    [No Abstract]   [Full Text] [Related]  

  • 25. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.
    Suzuki N; Kitazato K; Takamatsu J; Saito H
    Thromb Haemost; 1991 Apr; 65(4):369-73. PubMed ID: 1647552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolation and characterization of heparin from tuna skins.
    Jeske WP; McDonald MK; Hoppensteadt DA; Bau EC; Mendes A; Dietrich CP; Walenga JM; Coyne E
    Clin Appl Thromb Hemost; 2007 Apr; 13(2):137-45. PubMed ID: 17456622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of [3H]-heparin binding in human vascular smooth muscle cells and its relationship to the inhibition of DNA synthesis.
    Patel MK; Refson JS; Schachter M; Hughes AD
    Br J Pharmacol; 1999 May; 127(2):361-8. PubMed ID: 10385234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Marine glycosaminoglycan-like carbohydrates as potential drug candidates for infectious disease.
    Mycroft-West CJ; Yates EA; Skidmore MA
    Biochem Soc Trans; 2018 Aug; 46(4):919-929. PubMed ID: 30026370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The IUPAC International Congresses of Pesticide Chemistry (1963-2014) and Pest Management Science: a half-century of progress.
    Brooks GT
    Pest Manag Sci; 2014 Aug; 70(8):1165-8. PubMed ID: 24852234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparins. A pharmacologic overview.
    Hillis LB
    Adv Nurse Pract; 1997 Oct; 5(10):53-6. PubMed ID: 9459986
    [No Abstract]   [Full Text] [Related]  

  • 31. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.
    Jeske W; Lormeau JC; Callas D; Iqbal O; Hoppensteadt D; Fareed J
    Semin Thromb Hemost; 1995; 21(2):193-200. PubMed ID: 7660142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of polysaccharides enriched in 2,4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications.
    Fonseca RJ; Santos GR; Mourão PA
    Thromb Haemost; 2009 Nov; 102(5):829-36. PubMed ID: 19888516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. History of heparin.
    Barrowcliffe TW
    Handb Exp Pharmacol; 2012; (207):3-22. PubMed ID: 22566218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.
    Nasser NJ; Sarig G; Brenner B; Nevo E; Goldshmidt O; Zcharia E; Li JP; Vlodavsky I
    J Thromb Haemost; 2006 Mar; 4(3):560-5. PubMed ID: 16460439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.
    Bates SM; Weitz JI
    Br J Pharmacol; 2005 Apr; 144(8):1017-28. PubMed ID: 15711585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycosaminoglycans as naturally occurring combinatorial libraries: developing a mass spectrometry-based strategy for characterization of anti-thrombin interaction with low molecular weight heparin and heparin oligomers.
    Abzalimov RR; Dubin PL; Kaltashov IA
    Anal Chem; 2007 Aug; 79(16):6055-63. PubMed ID: 17658885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness.
    Lever R; Page C
    Pulm Pharmacol Ther; 2001; 14(3):249-54. PubMed ID: 11448151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unbalanced effects of dermatan sulfates with different sulfation patterns on coagulation, thrombosis and bleeding.
    Vicente CP; Zancan P; Peixoto LL; Alves-Sá R; Araújo FS; Mourão PA; Pavão MS
    Thromb Haemost; 2001 Nov; 86(5):1215-20. PubMed ID: 11816710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Historical overview of the WFN-organised Congresses on Parkinson's disease and related disorders.
    Battistin L; Korczyn AD; Wolters ECh
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S205-7. PubMed ID: 18267236
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.